Robert A. Belderbos
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.
Journal: The Lancet. Oncology
Published: December 21, 2023
Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 10, 2023
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
Journal: Cell reports. Medicine
Published: February 10, 2022
In Response to "Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision Making: A New Way of Counting".
Journal: JTO clinical and research reports
Published: November 04, 2021
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program.
Journal: Translational lung cancer research
Published: September 21, 2020
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 09, 2020
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma.
Journal: JTO clinical and research reports
Published: August 17, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Journal: Clinical lung cancer
Published: April 14, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Journal: Cancer immunology, immunotherapy : CII
Published: April 05, 2020
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
Journal: Journal for immunotherapy of cancer
Published: February 26, 2020
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
Journal: Frontiers in oncology
Published: September 15, 2019
Last Updated: 09/26/2026